Table 4.

Estimated risk ratios between baseline (T1) and follow-up (T2) EDS and methylation at various CpG sites, controlled for demographic and mood symptom variables. P-values are from partial Wald-type added-last tests of regression coefficients and adjusted for multiple comparisons post-hoc via the Benjamini-Hochberg procedure, controlling for a 5% FDR. McFadden pseudo-R² are provided for model fit.

Gene	CpG Site	Genome location (hg38)	EDS at T1			EDS at T2
			Risk Ratio (95% CI)	p-value	Pseudo-R2	Risk Ratio (95% CI)	p-value	Pseudo-R2
NR3C1	Site 1	chr5:143,404,073	0.85 (0.768,0.947)	0.008	0.170	0.98 (0.826,1.154)	0.891	0.145
	Site 2	chr5:143,404,071	0.84 (0.752,0.931)	0.004	0.174	0.84 (0.741,0.948)	0.025	0.167
	Site 3	chr5:143,404,061	0.92 (0.848,1.002)	0.110	0.162	0.71 (0.471,1.066)	0.234	0.187
	Site 4	chr5:143,404,056	0.95 (0.867,1.034)	0.308	0.158	0.93 (0.794,1.080)	0.442	0.148
BDNF	Site 1	chr11:27,701,672	1.03 (0.982,1.073)	0.308	0.158	1.00 (0.886,1.140)	0.937	0.144
	Site 2	chr11:27,701,668	1.02 (0.974,1.063)	0.477	0.156	1.05 (0.988,1.118)	0.234	0.151
	Site 3	chr11:27,701,657	0.91 (0.822,1.008)	0.123	0.161	0.88 (0.744,1.035)	0.234	0.151
	Site 4	chr11:27,701,644	0.96 (0.931,0.996)	0.065	0.163	0.98 (0.938,1.026)	0.503	0.147
	Site 5	chr11:27,701,616	0.96 (0.882,1.042)	0.376	0.157	0.86 (0.763,0.958)	0.025	0.161
	Site 6	chr11:27,701,612	0.86 (0.793,0.939)	0.004	0.176	0.89 (0.819,0.962)	0.025	0.167
	Site 7	chr11:27,701,597	0.92 (0.880,0.967)	0.004	0.175	0.92 (0.880,0.971)	0.025	0.169
FKBP5	Site 1	chr6:35,558,566	0.85 (0.787,0.919)	< 0.001	0.180	0.97 (0.907,1.031)	0.442	0.147
	Site 2	chr6:35,558,514	0.98 (0.945,1.012)	0.305	0.158	0.96 (0.893,1.025)	0.354	0.148